Email: cspc@cspc.cn
News
News Center
Jun. 10
2026
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR FIRST-LINE TRE
Jun. 08
SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jun. 02
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL STUDY DATA OF NOVEL B7-H3 ANTIBODY-DRUG CONJUGATE SYS6043 PRESENTED IN AN ORAL SESSION AT THE 2026 ASCO ANNUAL MEETING
Jun. 01
PHASE III CLINICAL STUDY RESULTS OF ANBENITAMAB (KN026) IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT OF HER2-P
May. 29
ENNITUO (ANBENITAMAB INJECTION) RECEIVES MARKETING AUTHORISATION FROM NMPA
May. 26
VOLUNTARY ANNOUNCEMENT - LANSOPRAZOLE ENTERIC-COATED CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
